Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases

World Journal of Surgical Oncology

Volumn 7, Issue , 2009, Pages 72-

  Abdel Misih, Sherif R Z ^a   Schmidt, Carl R ^a   Bloomston, Paul M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MACROSALB TC 99M; OXALIPLATIN; RADIOACTIVE MICROSPHERE; YTTRIUM 90;

ARTIFICIAL EMBOLISM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; CRYOABLATION; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; FATTY LIVER; HUMAN; IMAGE RECONSTRUCTION; LENGTH OF STAY; LIVER METASTASIS; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RECTUM CARCINOMA; REVIEW; SINUSOIDAL OBSTRUCTION SYNDROME; SURGICAL MORTALITY; SURGICAL RISK; SURGICAL TECHNIQUE; SURVIVAL RATE; THREE DIMENSIONAL IMAGING; CANCER STAGING; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; MORTALITY; PATHOLOGY; PATIENT CARE PLANNING; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT CARE PLANNING; PATIENT CARE TEAM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350717758     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-7-72     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Cli 2008, 58:71-96.
2. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007, 1:20-27. 2632517, 19262699.
3. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25:4575-4580. 10.1200/JCO.2007.11.0833, 17925551.
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77:1241-1246. 10.1002/bjs.1800771115, 2253003.
5. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006, 13:32-41.
6. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240:438-447. discussion 447-450, 10.1097/01.sla.0000138076.72547.b1, 1356434, 15319715.
7. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005, 241:715-722. discussion 722-724, 10.1097/01.sla.0000160703.75808.7d, 1357126, 15849507.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
9. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30. 10.1200/JCO.2004.09.046, 14665611.
10. Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Listrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988, 31:1-4. 10.1007/BF02552560, 3366020.
11. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995, 19:59-71. 10.1007/BF00316981, 7740812.
12. Bakalakos EA, Kim JA, Young DC, Martin EW. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 1998, 22:399-404. discussion 404-5, 10.1007/s002689900404, 9523523.
13. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. discussion 318-321, 10.1097/00000658-199909000-00004, 1420876, 10493478.
14. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statemen. Ann Surg Oncol 2006, 13:1261-1268. 10.1245/s10434-006-9023-y, 16947009.
15. Choti MA, Sitzman JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766. 10.1097/00000658-200206000-00002, 1422504, 12035031.
16. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?. Ann Surg 2008, 248:626-637.
17. Carpizo DR, D'Angelica M. Liver Resection for Metastatic Colorectal Cancer in the Presence of Extrahepatic Disease. Ann Surg Oncol 2009, 16:2411-2421. 10.1245/s10434-009-0493-6, 19554376.
18. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003, 90:567-574. 10.1002/bjs.4071, 12734864.
19. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005, 12:900-909. 10.1245/ASO.2005.01.010, 16184442.
20. Carpizo DR, Are C, Jarnagin W, DeMatteo R, Fong Y, Gonen M, Blumgart L, D'Angelica M. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009, 16:2138-2146. 10.1245/s10434-009-0521-6, 19495884.
21. Adam R, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay D, Bismuth H, Castaing D. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?. J Clin Oncol 2008, 26:3672-3680. 10.1200/JCO.2007.15.7297, 18669451.
22. Oussoultzoglou ERB, Panaro F, Rosso E, Pessaux P, Bachellier P, Jaeck D. Long-Term Survival After Liver Resection for Colorectal Liver Metastases in Patients with Hepatic Pedicle Lymph Nodes Involvement in the Era of New Chemotherapy Regimens. Annals of Surgery 2009, 249:879-886. 10.1097/SLA.0b013e3181a334d9, 19474695.
23. de Haas RJWD, Adam R. Resection of Colorectal Liver Metastases with Extrahepatic Disease. Digestive Surgery 2008, 25:461-466. 10.1159/000184737, 19212118.
24. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986, 73:727-731. 10.1002/bjs.1800730917, 3756436.
25. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999, 189:291-299. 10.1016/S1072-7515(99)00089-7, 10472930.
26. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 2006, 10:240-248. 10.1016/j.gassur.2005.07.027, 16455457.
27. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007, 14:1151-1160. 10.1245/s10434-006-9068-y, 17195913.
28. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000, 231:743-751. 10.1097/00000658-200005000-00015, 1421062, 10767796.
29. Melendez JA, Arslan V, Fischer ME, Wuest D, Jarnagin WR, Fong Y, Blumbgart LH. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998, 187:620-625. 10.1016/S1072-7515(98)00240-3, 9849736.
30. Wang WD, Liang LJ, Huang XQ, Yin XY. Low central venous pressure reduces blood loss in hepatectomy. World J Gastroenterol 2006, 12:935-939.
31. Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. Br J Surg 1998, 85:1058-1060. 10.1046/j.1365-2168.1998.00795.x, 9717995.
32. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, Barbas AS, Abdalla EK, Choti MA, Vauthey JN. Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional Analysis. Annals of Surgical Oncology 2007, 14:3481-3491. 10.1245/s10434-007-9522-5, 17805933.
33. Martin RC, Augenstein V, Reuter NP, Scoggins CR, McMasters KM. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 2009, 208:842-850. discussion 850-2, 10.1016/j.jamcollsurg.2009.01.031, 19476847.
34. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999, 6:651-657. 10.1007/s10434-999-0651-x, 10560850.
35. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, Morel P, Rubbia-Brandt L, Majno PE. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 2008, 25:430-435. 10.1159/000184734, 19212115.
36. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. J Clin Oncol 2009, 27:3379-84. 10.1200/JCO.2008.20.9817, 19487380.
37. Puthillath A, Dunn KB, Rajput A, Smith J, Yang G, Wilding GE, Tan W, Gupta B, Fakih MG. Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer. Clin Colorectal Cancer 2007, 6:710-715. 10.3816/CCC.2007.n.040, 18039424.
38. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990, 107:521-527.
39. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005, 16:779-790.
40. Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, Momose Y, Komiyama A, Makuuchi M. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995, 21:1317-1321. 10.1002/hep.1840210515, 7737637.
41. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000, 127:512-519. 10.1067/msy.2000.105294, 10819059.
42. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002, 137(6):675-680. 10.1001/archsurg.137.6.675, 12049538.
43. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000, 232:777-785. 10.1097/00000658-200012000-00006, 1421270, 11088072.
44. Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G, Aloia T. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 2007, 16:525-536. viii, 10.1016/j.soc.2007.04.016, 17606192.
45. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004, 240:1037-1049. discussion 1049-1051, 10.1097/01.sla.0000145965.86383.89, 1356519, 15570209.
46. Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, Greget M. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg 2003, 185:221-229. 10.1016/S0002-9610(02)01373-9, 12620560.
47. Shimada H, Tanaka K, Masui H, Nagano Y, Matsuo K, Kijima M, Ichikawa Y, Ike H, Ooki S, Togo S. Results of surgical treatment for multiple (> or = 5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg 2004, 389:114-121. 10.1007/s00423-003-0447-6, 14714186.
48. Garcea G, Polemonivi N, O'Leary E, Lloyd TD, Dennison AR, Berry DP. Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases. Eur J Surg Oncol 2004, 30:759-764. 10.1016/j.ejso.2004.05.009, 15296990.
49. Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D, Endo I, Wekido H, Ike H, Shimada H. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology 2005, 52:913-919.
50. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005, 23:9243-9249. 10.1200/JCO.2005.07.740, 16230673.
51. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016. 10.1016/S0140-6736(08)60455-9, 2277487, 18358928.
52. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992. 10.1093/annonc/mdn735, 19153115.
53. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998, 25:40-46.
54. Delaunoit T, Alberts SR, Sargen DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005, 16:425-429. 10.1093/annonc/mdi092, 15677624.
55. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term surviva. Ann Surg 2004, 240:644-657. discussion 657-658, 10.1097/01.sla.0000145964.08365.01, 1356466, 15383792.
56. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006, 243:1-7. 10.1097/01.sla.0000193603.26265.c3, 1449955, 16371728.
57. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072. 10.1200/JCO.2005.05.3074, 16648507.
58. Abdalla EK, Vauthey JN. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful?. Dig Surg 2008, 25:421-429. 10.1159/000184733, 19212114.
59. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007, 94:274-2786. 10.1002/bjs.5719, 17315288.
60. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24:4983-4990. 10.1200/JCO.2006.05.8156, 17075116.
61. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568. 10.1016/S1470-2045(09)70112-3, 19482548.
62. Beatty GL, Giantonio BJ. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Rev Anticancer Ther 2008, 8:683-688. 10.1586/14737140.8.5.683, 18471041.
63. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008, 15:2765-2772. 10.1245/s10434-008-0035-7, 18636296.
64. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003, 10:338-347. 10.1245/ASO.2003.07.017, 12734080.
65. van Duijnhoven FH, Jansen MC, Junggeburt JM, van Hillegersberg R, Rijken AM, van Coevorden F, Sijp JR, van Gulik TM, Slooter GD, Klaase JM. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006, 13:651-658. 10.1245/ASO.2006.08.014, 16538411.
66. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006, 141:460-466. discussion 466-467, 10.1001/archsurg.141.5.460, 16702517.
67. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003, 90:1240-1243. 10.1002/bjs.4264, 14515293.
68. Mulier S, Ruers T, Jamart J, Michel L, Marchal G, Ni Y. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update. Dig Surg 2008, 25:445-460. 10.1159/000184736, 19212117.
69. Siperstein A, Garland A, Engle K, Rogers S, Berber E, Foroutani A, String A, Ryan T, Ituarte P. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000, 7:106-113. 10.1007/s10434-000-0106-x, 10761788.
70. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999, 230:1-8. 10.1097/00000658-199907000-00001, 1420837, 10400029.
71. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-825. discussion 825-827, 10.1097/01.sla.0000128305.90650.71, 1356290, 15166961.
72. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007, 33:67-71.
73. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007, 246:559-565. discussion 565-567, 10.1097/SLA.0b013e318155a7b6, 17893492.
74. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005, 23:1358-1364. 10.1200/JCO.2005.12.039, 15684312.
75. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001, 221:159-166. 10.1148/radiol.2211001624, 11568334.
76. Scaife CL, Curley SA. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin N Am 2003, 12:243-255. 10.1016/S1055-3207(02)00088-1, 12735142.
77. Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg 2002, 6:255-263. 10.1016/S1091-255X(02)00002-1, 11992812.
78. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg 2006, 141:581-587. discussion 587-588, 10.1001/archsurg.141.6.581, 16785359.
79. Stippel DL. [Percutaneous, laparoscopic and open surgical radiofrequency ablation of malignant liver lesions]. Zentralbl Chir 2007, 132:293-239. 10.1055/s-2007-981198, 17724630.
80. Burdio F, Mulier S, Navarro A, Figueras J, Berjano E, Poves I, Grande L. Influence of approach on outcome in radiofrequency ablation of liver tumors. Surg Oncol 2008, 17:295-299. 10.1016/j.suronc.2008.03.002, 18472417.
81. Mulier S, Ruers T, Jamart J, Michel L, Marchal G, Ni Y. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008, 15:144-157. 10.1245/s10434-007-9478-5, 17906898.
82. Garrean S, Hering J, Saied A, Helton WS, Espat NJ. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008, 195:508-520. 10.1016/j.amjsurg.2007.06.024, 18361927.
83. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008, 15:2757-2764. 10.1245/s10434-008-0043-7, 18618182.
84. Iannitti DA, Martin RC, Simon CJ, Hope WW, Newcomb WL, McMasters KM, Dupuy D. Hepatic tumor ablation with clustered microwave antennae: the US Phase II Trial. HPB (Oxford) 2007, 9:120-124. 2020783, 18333126.
85. Scoggins CR, JFGJ, Martin RCG, Kehdy FJ, Hutchinson JR, McMasters KM. Thermal ablation of liver tumors. Cancer Therapy 2004, 2:455-462.
86. Martin RC. Hepatic tumor ablation: cryo versus radiofrequency, which is better?. Am Surg 2006, 72:391-392.
87. Fahy BN, Jarnagin WR. Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. Surg Clin North Am 2006, 86:1005-1022. 10.1016/j.suc.2006.06.003, 16905421.
88. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005, 352:734-735. 10.1056/NEJM200502173520723, 15716576.
89. South CD, Meyer MM, Meis G, Kim EY, Thomas FB, Rikabi AA, Kahbiri H, Bloomston M. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol 2008, 6:93. 10.1186/1477-7819-6-93, 2533667, 18764938.
90. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007, 18:553-561. quiz 562, 10.1016/j.jvir.2007.02.002, 17446547.
91. Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg 2007, 142:675-682. 10.1001/archsurg.142.7.675, 17638807.
92. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65:412-425.
93. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25:1099-1106. 10.1200/JCO.2006.08.7916, 17369573.
94. Goldstein GvH D, Pavlakis N, Olver I. Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with Irinotecan. A phase I dose escalation study. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2005, 23. Abstract 3701.
95. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001, 5:294-302. 10.1016/S1091-255X(01)80051-2, 11360053.
96. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006, 76:696-703. 10.1111/j.1445-2197.2006.03834.x, 16916386.
97. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000, 231:487-499. 10.1097/00000658-200004000-00006, 1421023, 10749608.